Source-grounded facts extracted from Hongchang International Co., Ltd's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hongchang International Co., Ltd: Company changed fiscal year end from December 31 to March 31 (effective 2025-05-12).
“On May 12, 2025, the board of directors of Hongchang International Co., Ltd (the “Company”) approved a change in the Company’s fiscal year end from December 31 to March 31.”
Hongchang International Co., Ltd engaged Enrome LLP as its auditor.
“On April 24, 2025, the Board have approved the engagement of Enrome as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements as of and for the fiscal year ending December 31, 2025, effective April 24, 2025.”
Hongchang International Co., Ltd dismissed WWC, P.C. as its auditor.
“On April 24, 2025, the Board of Directors (the “ Board ”) of Hongchang International Co., Ltd, a Nevada corporation (the “ Company ”), approved the appointment of Enrome LLP (“ Enrome ”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and dismissed WWC, P.C. (“ WWC ”), effective April 24, 2025.”
Qingqing Wang resigned as Board Secretary at Hongchang International Co., Ltd.
“On April 24, 2025, Ms. Qingqing Wang, the Board Secretary of the Company, notified the Board that she was resigning from the Board Secretary, effective as of April 24, 2025.”
Zengqiang Lin was appointed as Chairman of the Board at Hongchang International Co., Ltd.
“Effective as of April 24, 2025, Mr. Zengqiang Lin, Chief Executive Officer, Chief Financial Officer, President and a director of the Company, was appointed as the Chairman of the Board of the Company.”
Ban Siong Ang resigned as Chairman of the Board at Hongchang International Co., Ltd.
“On April 24, 2025, Mr. Ban Siong Ang, a director and the Chairman of the Board of the Company, notified the Board that he was resigning from Chairman of the Board due to personal reasons, effective as of April 24, 2025.”
Zengqiang Lin was appointed as Chief Financial Officer at Hongchang International Co., Ltd.
“Effective May 8, 2024, Mr. Zengqiang Lin was appointed as the Chief Financial Officer of the Company, in addition to his appointments as the Chief Executive Officer and Director of the Company.”
Xingjia Gao resigned as Director at Hongchang International Co., Ltd.
“Effective May 8, 2024, Mr. Xingjia Gao resigned as a Director from the Board of the Company, due to personal reasons.”
Wendy Li resigned as Chief Financial Officer at Hongchang International Co., Ltd.
“Effective May 8, 2024, Ms. Wendy Li resigned as the Chief Financial Officer of Hongchang International Co., Ltd (the “Company”), due to personal reasons.”
Qingqing Wang was appointed as Board Secretary at Hongchang International Co., Ltd.
“Effective March 27, 2024, Ms. Qingqing Wang was appointed as a Board Secretary of the Company by the Board.”
Stephan Truly Busch resigned as director at Hongchang International Co., Ltd.
“Effective March 27, 2024, Mr. Stephan Truly Busch resigned as a director of Hongchang International Co., Ltd (the “Company”).”
Hongchang International Co., Ltd: Amended and restated bylaws adopted on November 23, 2023, with changes regarding exercise of corporate powers by board as a whole, director authority limited to board resolutions, and president presiding at meetings if also a director and no chairman of the board (effective 2023-11-23).
“On November 23, 2023, the Board of Directors (the “Board”) of Hongchang International Co., Ltd (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day.”
Hongchang International Co., Ltd: Company amended Articles of Incorporation to change name from Heyu Biological Technology Corporation to Hongchang International Co., Ltd (effective 2023-11-17).
“On November 17, 2023, the Company amended its Articles of Incorporation with the Nevada Secretary of State (“Charter Amendment”) to effect the name change of the Company from “Heyu Biological Technology Corporation” to “Hongchang International Co., Ltd.””
Hongchang International Co., Ltd completed a disposition involving Ban Siong Ang (closed 2023-09-04).
“The Share Disposal was consummated on September 4, 2023.”
Hongchang International Co., Ltd completed an acquisition involving Zengqiang Investment Limited and Hong Jin Investment Limited for 353,322,843 shares of our common stock to Zengqiang Investment Limited, and 62,259,532 shares of our common stock to Hong Jin Investment Limited (closed 2023-09-04).
“In accordance with the terms of the Share Exchange Agreement, on September 4, 2023, the Selling Shareholders transferred 100 shares of Hongchang BVI, constituting one hundred percent (100%) of the issued and outstanding share capital of Hongchang BVI, to our Company in exchange for the issuance of 353,322,843 shares of our common stock to Zengqiang Investment Limited, and 62,259,532 shares of our common stock to Hong Jin Investment Limited.”
Hongchang International Co., Ltd entered into Share Exchange Agreement with Zengqiang Investment Limited and Hong Jin Investment Limited valued at an aggregate of 415,582,375 new shares of our Company’s common stock (effective 2023-08-21).
“On August 21, 2023, our Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Hongchang BVI, a business company incorporated in the BVI, and Hongchang BVI’s shareholders, Zengqiang Investment Limited, a business company incorporated in the BVI, and Hong Jin Investment Limited, a business company incorporated in the BVI (the “Selling Shareholders” and each a “Selling Shareholder”), in relation to the acquisition of Hongchang BVI by our Company (the “Hongchang Acquisition”).”
Hongchang International Co., Ltd completed a disposition involving Mr. Ban Siong Ang for nominal consideration.
“On August 21 2023, we entered into a share purchase agreement (“Share Purchase Agreement”) with our Director, Mr. Ban Siong Ang as the buyer, to dispose of our existing assets”
Hongchang International Co., Ltd completed an acquisition involving Hong Chang Global Investment Holdings Limited for 415,582,375 new shares of our Company’s common stock (closed 2023-08-21).
“will sell and transfer 100 shares of Hongchang BVI, constituting all of the issued and outstanding share capital of Hongchang BVI, to our Company in exchange for an aggregate of 415,582,375 new shares of our Company’s common stock (the “Consideration Shares”), of which 353,322,843 shares will be issued to Zengqiang Investment Limited and 62,259,532 shares will be”
Hongchang International Co., Ltd entered into Share Exchange Agreement with Hong Chang Global Investment Holdings Limited (Hongchang BVI) and its shareholders, Zengqiang Investment Limited and Hong Jin Investment Limited valued at 415,582,375 new shares of common stock (effective 2023-08-21).
“On August 21, 2023, our Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Hong Chang Global Investment Holdings Limited (“Hongchang BVI”), a business company incorporated in the British Virgin Islands (“BVI”), and Hongchang BVI’s shareholders, Zengqiang Investment Limited, a business company incorporated in the BVI, and Hong Jin Investment Limited, a business company incorporated in the BVI (the “Selling Shareholders” and each a “Selling Shareholder”), in relation to the acquisition of Hongchang BVI by our Company (the “Hongchang Acquisition”).”
Hongchang International Co., Ltd: Certificate of Amendment effecting a one-for-ten reverse stock split (effective 2023-08-08).
“On August 8, 2023, Heyu Biological Technology Corporation (the “Company”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) with the State of Nevada, which has effected a one-for-ten reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock, par value $0.001 per share (the “Common Stock”).”
Zengqiang Lin was appointed as independent director at Hongchang International Co., Ltd.
“On February 17, 2023, the board of directors of Heyu Biological Technology Corporation (the “Company”) announced the appointment of Mr. Zengqiang Lin as an independent director of the Company, effective immediately.”
Bo Lyu was appointed as Chief Financial Officer at Hongchang International Co., Ltd.
“On November 30,2021, Mr. Bo Lyu was appointed by the board of directors of Heyu Biological Technology Corporation (the “Company”) as the Company’s Chief Financial Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.